KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.95

Long-term follow-up of a randomized, double-blind, phase III, multi-centre study to evaluate the safety and efficacy of field-directed photodynamic therapy (PDT) of mild to moderate actinic keratosis using BF-200 ALA versus placebo and the BF-RhodoLED® lamp.

U Reinhold, W G Philipp-Dormston, T Dirschka, R Ostendorf, R Aschoff, C Berking, A Jäger, B Schmitz, M Foguet, R-M Szeimies

J Eur Acad Dermatol Venereol 39(8) 1449-1459

PMID39666443
PMCIDPMC12291023
DOI10.1111/jdv.20452
发表日期2024-12-12
入排依据:The study is a Phase III randomized trial in actinic keratosis (pre-malignant) evaluating photodynamic therapy with BF-200 ALA vs placebo. While it is oncology-related and reports original results, the primary efficacy endpoint is not a time-to-event outcome (e.g., OS, PFS, DFS) but rather response/recurrence rates at specific time points. The study does not report Kaplan-Meier curves or hazard ratios for survival or time-to-event endpoints.
已检查 5 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 flow diagram;FIGURE 2:AI 判定为 other;FIGURE 3:森林图/亚组分析图;FIGURE 4:AI 判定为 other;FIGURE 5:AI 判定为 other。
摘要

摘要

BACKGROUND: In actinic keratosis (AK), field cancerization describes areas of skin where multiple visible AK lesions are surrounded by healthy looking skin containing non-visible (subclinical) lesions. As all AK lesions have a risk of progression to cutaneous squamous cell carcinoma, experts advise field-directed treatment. Photodynamic therapy (PDT) is an effective field-directed treatment option for AK; however, long-term efficacy data are still scarce. OBJECTIVES: This publication presents follow-up data of a phase III study evaluating the efficacy and safety of field-directed PDT. METHODS: The study was conducted in seven centres in Germany. For PDT, participants with AKs on the face and scalp (treatment area of 20 cm2) had received up to two field-directed PDTs using BF-200 ALA or placebo, and illumination with narrow-spectrum red light. Only participants or lesions with complete response 12 weeks after the last PDT were assessed for recurrences. The treatment area was evaluated 6 and 12 months after the last PDT for recurrence, cosmetic outcome and new lesions. RESULTS: Fifty-four participants in the BF-200 ALA and 30 in the placebo group entered the follow-up. The probability of a participant to be initially completely cleared and to remain cleared for 12 months was 57.4% for BF-200 ALA versus 20.0% for placebo. The probability of a lesion to be initially cleared and remain cleared for 12 months was 85.4% for BF-200 ALA versus 31.5% for placebo. 83.3% of participants with cosmetic impairment at baseline rated the cosmetic outcome 12 months after PDT with BF-200 ALA as very good or good. All parameters of skin quality further improved during follow-up. CONCLUSIONS: We showed that effectiveness of field-directed PDT with BF-200 ALA and narrow-spectrum red light was maintained during follow-up. Based on our results, field-directed PDT is a beneficial long-lasting treatment for AK patients. CLINICAL TRIAL REGISTRATION NUMBERS: 2013-002510-12 (EudraCT); NCT01966120 (Clinicaltrials.gov).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 Disposition of participants. A total of 84 participants entered the follow‐up, 54 in the BF‐200 ALA group (left) and 30 in the placebo group (right). Eighty participants completed the follow‐up (54 in the BF‐200 ALA group, 26 in the placebo group). ALA, 5‐aminolevulinic acid; FAS, full analysis set; n , number of participants; PDT, photodynamic therapy; PPP, per‐protocol population.
非 KM Figure
FIGURE 2FIGURE 2 Participant recurrence rates during follow‐up. Participants who entered the follow‐up and showed complete lesion clearance 12 weeks after PDT were assessed for recurrence after 6 and 12 months. Left: Participants treated with PDT using BF‐200 ALA; right: Participants treated with PDT using placebo. Bars at the top show proportion of participants entering the follow‐up completely cleared or as non‐responders. Bar charts below show the percentage of participants who remained clear at the respective follow‐up visit. Data are presented for the full analysis set of the follow‐up. BF‐200 ALA, nanoemulsion gel containing 7.8% aminolevulinic acid; PDT, photodynamic therapy.
非 KM Figure
FIGURE 3FIGURE 3 Participant recurrence rates in follow‐up by subgroups (BF‐200 ALA). Participants who entered the follow‐up and showed complete clearance of actinic keratosis target lesions 12 weeks after PDT were assessed for recurrence after 6 and 12 months. Bar charts show participant recurrence rates (%) for the subgroups maximum AK severity at baseline (a), age (b), sex (c), skin type (d), treatment areas (e), numbers of AK lesions at baseline (f), and total AK area at baseline (g). Number of recurrent participants in each subgroup ( n ) as part of the total number of participants in this respective subgroup ( N ) is stated above each bar graph as n / N . Data are presented for the full analysis set of the follow‐up. AK, actinic keratosis; BF‐200 ALA, nanoemulsion gel containing 7.8% aminolevulinic acid; PDT, photodynamic therapy.
非 KM Figure
FIGURE 4FIGURE 4 Lesion recurrence rates during follow‐up. Of all lesions included in the follow‐up, completely cleared lesions were assessed for recurrence 6 and 12 months after PDT. Left: Lesions treated with PDT using BF‐200 ALA; right: Lesions treated with PDT using placebo. Bars at the top show proportion of lesions included in the follow‐up completely cleared or as non‐responding. Bar charts below show the percentage of lesions who remained clear at the respective follow‐up visit. Data are presented for the full analysis set of the follow‐up. BF‐200 ALA, nanoemulsion gel containing 7.8% aminolevulinic acid; PDT, photodynamic therapy.
非 KM Figure
FIGURE 5FIGURE 5 Proportions of participants with impairment of skin quality before and after field‐directed PDT. Skin quality was assessed for different parameters on a 4‐point scale from 0 to 3 (none, mild, moderate, severe). Assessments were performed before treatment (baseline), 12 weeks, and 6 and 12 months after the last PDT. Graphs show percentages of participants with any impairment regarding the respective parameter of skin quality. Data are presented for the full analysis set of the follow‐up (baseline, 6 and 12 months after the last PDT). Data for 12 weeks after the last PDT taken from Reinhold et al. were added for completeness. BF‐200 ALA, nanoemulsion gel containing 7.8% aminolevulinic acid; PDT, photodynamic therapy.
非 KM Figure